A drawback of CAS is that it is considerably more expensive than CEA. 4 Another concern is the reproducibility/ generalizability of CAS results from randomized controlled trials (like the ones mentioned by Dr Besli) 2 into "real-life" clinical practice. A systematic review of >1 500 000 CAS and CEA procedures from 21 registries on asymptomatic patients showed that CAS was associated with similar stroke/death rates with CEA in only 5 (24%) of 21 registries. 5 In more than half of the registries (11 of 21; 52%), CAS was associated with significantly higher stroke/death rates compared with CEA. In the remaining 5 (24%) registries, stenting was once again associated with higher stroke/death rates compared with CEA, but a formal statistical comparison had not been performed. 5 More importantly, CAS was associated with stroke/death rates that exceeded the 2017 ESVS-recommended thresholds (<3%) 3 in 9 (43%) of the 21 registries. 5 Finally, in one-third of the registries (7 of 21; 33%), CAS was associated with death/stroke rates 4%.
5 Embolic protection devices were not available at the time or were not used in many of these registries. Although EPDs have advantages (eg, reduction of embolic events associated with CAS), their use is also associated with certain disadvantages (eg, technical difficulties in traversing the lesion at the time of CAS, additional risk of embolization during device manipulation, additional contrast material used, etc). 6 Although these risks are small with experienced operators, they are not negligible. Recent improvements with the use of transcervical devices are yet to be evaluated in randomized trials. Finally, EPDs also add to the already high cost of CAS.
Nobody disputes the fact that CAS has a role in the management of asymptomatic carotid patients, but this role is currently small given the lack of cost-effectiveness of the procedure compared with CEA 4 and the suboptimal CAS results reported in real-life registries. 5 The majority of asymptomatic patients should be managed with best medical treatment. 1 Those requiring a carotid intervention should ideally get CEA instead of CAS. Asymptomatic patients at high risk of becoming symptomatic who are also at higher surgical risk with CEA (eg, patients with cardiac insufficiency or chronic obstructive pulmonary disease) could potentially be candidates for CAS, but the life expectancy of such patients often does not exceed 5 years (as recommended by the ESVS Guidelines) 3 to justify an invasive procedure. Another disadvantage of CAS (which is often underestimated and/or ignored) is contrastinduced acute kidney injury. 7, 8 Insertion of an EPD will require more contrast medium and more radiation, although these factors may be minimal in the hands of experienced operators. Further improvements of CAS results in the future may render more asymptomatic patients suitable for the procedure.
